• +1-646-491-9876
    • +91-20-67278686

    Search

    Axial Spondyloarthritis-Pipeline Review H1 2017

    Axial Spondyloarthritis-Pipeline Review H1 2017

    • Report Code ID: RW0001834321
    • Category Pharmaceuticals
    • No. of Pages 111
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Axial Spondyloarthritis - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Axial Spondyloarthritis - Pipeline Review, H1 2017, provides an overview of the Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline landscape.

    Axial spondylitis is a type of inflammatory arthritis involving the spine and/or sacroiliac joints. Axial spondylitis is strongly related to the presence of the HLA-B27 gene. A genetic test for HLA-B27 is available.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Axial Spondyloarthritis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Axial Spondyloarthritis (Musculoskeletal Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Axial Spondyloarthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase I, Preclinical and Unknown stages are 2, 6, 1, 2 and 1 respectively.

    Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Axial Spondyloarthritis (Musculoskeletal Disorders) .
    - The pipeline guide reviews pipeline therapeutics for Axial Spondyloarthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Axial Spondyloarthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Axial Spondyloarthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Axial Spondyloarthritis (Musculoskeletal Disorders)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Axial Spondyloarthritis (Musculoskeletal Disorders) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Axial Spondyloarthritis - Overview
    Axial Spondyloarthritis - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Axial Spondyloarthritis - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Axial Spondyloarthritis - Companies Involved in Therapeutics Development
    AstraZeneca Plc
    Eli Lilly and Company
    Johnson & Johnson
    Novartis AG
    Panacea Biotec Ltd
    Sandoz International GmbH
    Sun Pharma Advanced Research Company Ltd
    UCB SA
    Axial Spondyloarthritis - Drug Profiles
    adalimumab biosimilar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    adalimumab biosimilar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    adalimumab biosimilar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    adalimumab biosimilar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    brodalumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    certolizumab pegol - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    etanercept biosimilar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ixekizumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    secukinumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Antagonize ROR-Gamma for Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tildrakizumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ustekinumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Axial Spondyloarthritis - Dormant Projects
    Axial Spondyloarthritis - Product Development Milestones
    Featured News & Press Releases
    Apr 24, 2017: Kyowa Hakko Kirin Announces Initiation of Global Phase 3 Study of KHK4827 (Brodalumab) in Patients with Axial Spondyloarthritis (axSpA)
    Apr 21, 2017: Sandoz Receives CHMP Positive Opinion For Erelzi
    Mar 06, 2017: First CIMZIA Study of Its Kind Showed Minimal to No Transfer of Drug from Mother's Plasma to Breast Milk
    Nov 11, 2016: UCB Presents Data on Cimzia (certolizumab pegol) at 2016 ACR/ARHP Annual Meeting
    Oct 25, 2016: Certolizumab pegol (Cimzia) AutoClicks Prefilled Pen - a New Self-injection Device Designed in Collaboration With Patients and Good Grips - is Now Available in the UK on the NHS
    Jun 08, 2016: UCB commitment to addressing real world patient needs on display at the Annual European Congress of Rheumatology (EULAR 2016)
    Nov 06, 2015: UCB Presents Latest Research from Immunology Portfolio at American College of Rheumatology Annual Meeting
    Nov 14, 2014: UCB Shows Strong Scientific Presence On Certolizumab pegol (CIMZIA) At Leading Rheumatology Meeting
    Sep 20, 2013: UCB receives CHMP positive opinion for Cimzia in severe active axial spondyloarthritis
    Jul 24, 2013: U.S. FDA Arthritis Advisory Committee Votes On Cimzia For Treatment of Adults with Active Axial Spondyloarthritis, Including Patients with Ankylosing Spondylitis
    Jun 14, 2013: UCB's Certolizumab Pegol Rapidly Improves Pain, Fatigue And Physical Function In axSpA Patients In Phase III Study
    Feb 20, 2013: UCB Announces Regulatory Filings For Cimzia To Treat Psoriatic Arthritis And Axial Spondyloarthritis
    Nov 13, 2012: UCB Announces Presentation Of Phase III Trial Results Of Certolizumab Pegol In Axial Spondyloarthritis At ACR 2012 Annual Meeting
    Nov 09, 2012: UCB To Present New Data On Certolizumab Pegol At ACR's 2012 Annual Scientific Meeting
    Apr 16, 2012: UCB Announces Positive Top-Line Phase III Results Of Cimzia In Axial Spondyloarthritis And Ankylosing Spondylitis
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Axial Spondyloarthritis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Axial Spondyloarthritis - Pipeline by AstraZeneca Plc, H1 2017
    Axial Spondyloarthritis - Pipeline by Eli Lilly and Company, H1 2017
    Axial Spondyloarthritis - Pipeline by Johnson & Johnson, H1 2017
    Axial Spondyloarthritis - Pipeline by Novartis AG, H1 2017
    Axial Spondyloarthritis - Pipeline by Panacea Biotec Ltd, H1 2017
    Axial Spondyloarthritis - Pipeline by Sandoz International GmbH, H1 2017
    Axial Spondyloarthritis - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017
    Axial Spondyloarthritis - Pipeline by UCB SA, H1 2017
    Axial Spondyloarthritis - Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development for Axial Spondyloarthritis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    AstraZeneca Plc
    Eli Lilly and Company
    Johnson & Johnson
    Novartis AG
    Panacea Biotec Ltd
    Sandoz International GmbH
    Sun Pharma Advanced Research Company Ltd
    UCB SA

    Request for Sample

    Report Url http://www.reportsweb.com//axial-spondyloarthritis-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//axial-spondyloarthritis-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//axial-spondyloarthritis-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments